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Introductory Article
A Clinical Practice Guideline for the
Management of Degenerative Cervical
Myelopathy: Introduction, Rationale,
and Scope
Michael G. Fehlings, MD, PhD, FRCSC, FACS1,2,
Lindsay A. Tetreault, PhD1,3, K. Daniel Riew, MD4,
James W. Middleton, MBBS, PhD5, and Jeffrey C. Wang, MD6
Abstract
Degenerative cervical myelopathy (DCM) is a progressive spine disease and the most common cause of spinal cord dysfunction in
adults worldwide. Patients with DCM may present with common signs and symptoms of neurological dysfunction, such as
paresthesia, abnormal gait, decreased hand dexterity, hyperreflexia, increased tone, and sensory dysfunction. Clinicians across
several specialties encounter patients with DCM, including primary care physicians, rehabilitation specialists, therapists, rheu-
matologists, neurologists, and spinal surgeons. Currently, there are no guidelines that outline how to best manage patients with
mild (defined as a modified Japanese Orthopedic Association (mJOA) score of 15-17), moderate (mJOA ¼ 12-14), or severe
(mJOA  11) myelopathy, or nonmyelopathic patients with evidence of cord compression. This guideline provides evidence-
based recommendations to specify appropriate treatment strategies for these populations. The intent of our recommendations is
to (1) help identify patients at high risk of neurological deterioration, (2) define the role of nonoperative and operative man-
agement in each patient population, and (3) determine which patients are most likely to benefit from surgical intervention. The
ultimate goal of these guidelines is to improve outcomes and reduce morbidity in patients with DCM by promoting standardi-
zation of care and encouraging clinicians to make evidence-informed decisions.
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Introduction and Background Information
Degenerative cervical myelopathy (DCM) is a progressive
degenerative spine disease and the most common cause of spinal
cord dysfunction in adults worldwide.1,2 The underlying patho-
physiology involves age-related degeneration of the tissues of
the spinal column, resulting in static spinal cord compression,
and repetitive dynamic injury due to increased spinal column
mobility.3 The structural changes involved in DCM include (1)
degeneration of intervertebral discs, vertebral bodies, and facet
joints; (2) hypertrophy of the ligamentum flavum; and (3) ossi-
fication of the posterior longitudinal ligament (OPLL).4 These
changes significantly narrow the spinal canal and reduce the
space available for the spinal cord. Compression of the spinal
cord results in a series of pathobiological events, which may
impair normal neurological function and cause irreversible cyto-
logical and histological damage: (1) ischemia and alterations of
vascular architecture, (2) endothelial cell impairment and dis-
ruption of the blood spinal cord barrier, (3) neuroinflammation,
and (4) oligodendrocyte and neuronal apoptosis.5,6
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Aging initially leads to biochemical and biomechanical
alterations to the spine, which can progress to micro- and
macrostructural changes to its anatomy.7 The degenerative pro-
cess begins as the discs degenerate and can no longer maintain
their weight-bearing and load-transferring functions.8 As a
result, there is increased stress on the articular cartilage end-
plates which results in synovial inflammation, joint space nar-
rowing and facet hypertrophy. Compensatory mechanisms
include (1) development of osteophytes to increase the
surface area of the endplates and to stabilize abnormal spinal
mobility, (2) stiffening and buckling of the ligamentum
flavum in response to reduced disc height and straightening
of cervical lordosis, and (3) hypertrophy or ossification of other
ligaments. In the most recent evaluation of asymptomatic
patients, Nakashima et al9 reported significant disc bulging in
87.6% of volunteers aged 20 to 79 years. Others studies have
identified that 70% to 95% of individuals aged 60 to 65 years
display evidence of degenerative changes on lateral cervical
spine radiographs10 and that 86% of subjects over the age of
60 years exhibit varying degrees of disc degeneration.11
Although spinal degeneration is common in the elderly
population, only a small portion will eventually develop
myelopathy.
Patients with significant spinal cord compression may pres-
ent with common signs and symptoms of neurological dysfunc-
tion. The underlying degenerative spinal pathology may cause
localized and radiating neck pain.1,12 Neurological symptoms
include paresthesia (numbness and tingling), abnormal gait/
balance and falls, decreased hand dexterity, and sphincter dys-
function. Concomitant radicular pain and weakness may also
be present from spinal nerve root compression. Signs on clin-
ical examination include upper motor neuron features of hyper-
reflexia and increased (spastic) tone, sensory and motor
dysfunction, and gait abnormality. DCM is diagnosed when a
patient presents with signs and symptoms consistent with mye-
lopathy and image (usually magnetic resonance imaging
[MRI]) evidence of spinal cord compression.
Differential diagnoses of the clinical presentation are impor-
tant to consider, including intracranial, demyelinating, motor
neuron, infectious, inflammatory, and metabolic diseases.13 In
a recent narrative review, Kim et al13 identified multiple sclero-
sis, vitamin B12 deficiency, amyotrophic lateral sclerosis, and
peripheral nerve entrapment as the major differential diagnoses
of DCM. This review concluded that a combination of clinical
and imaging findings is necessary to confirm the diagnosis of
DCM and to rule out other diagnoses.
Previous Guidelines
In 2009, the Joint Section on Disorders of the Spine and Per-
ipheral Nerves of the American Association of Neurological
Surgeons/Congress of Neurological Surgeons undertook an ini-
tiative to develop recommendations for the surgical management
of cervical degenerative disease. Topics in this focus issue
included the natural history of DCM, clinical and imaging pre-
dictors of surgical outcome, surgical techniques (laminectomy,
laminoplasty, and anterior decompression), functional assess-
ment tools, management of pseudoarthrosis, and electrophysio-
logical monitoring during surgery. Recommendations for each
of these topics were formulated by a panel of experts in ortho-
pedic or neurosurgery and were based primarily on an assess-
ment of the current body of evidence. Expert consensus was used
to develop each recommendation and to assign a final grade for
strength.
In 2013, a second focus issue on DCM was published in
Spine and included recommendations and consensus state-
ments for the natural history of DCM, predictors of neurologic
dysfunction in the nonmyelopathic patient, nonoperative man-
agement, differential diagnosis, imaging predictors of outcome,
ancillary outcome assessment tools, genetics and heritability,
the influence of spinal deformity on management, and surgical
treatments. Similarly, these recommendations and statements
were formulated through expert consensus and a Delphi
procedure.
The current guidelines complement the existing focus
issues. In addition, the development of these recommendations
(1) adhered to current methodological standards; (2) incorpo-
rated the opinions of experts in the fields of spine surgery,
neurology, rheumatology, rehabilitation medicine, physiatry,
and primary care; and (3) considered factors other than the
strength of existing evidence, including patient values,
resource use, balance of benefits and harms, acceptability, fea-
sibility, and impact on health inequities. These guidelines will
provide important recommendations for the management of
patients with mild, moderate, and severe disease as well as
nonmyelopathic patients with image evidence of canal stenosis
and/or cord compression and will consider disease natural his-
tory; operative and nonoperative management; and predictors
of myelopathy development, neurological deterioration, and
treatment outcomes.
Rationale and General Scope
There are several important reasons for developing guidelines
for the management of patients with DCM. First, according to
the World Health Organization, the proportion of the popula-
tion older than 60 years is projected to double from 11% in
2010 to 22% in 2050.7 The aging of the population will be
accompanied by an “epidemiologic transition” from commu-
nicable to noncommunicable disease and an increase in
age-related disorders of the spine, including DCM.7 This
unprecedented upward shift in the age structure of the global
population will pose unique challenges to health care systems
worldwide as elderly patients tend to have multiple medical
comorbidities, decreased mobility, poor balance, a greater
propensity to falls and more severe spinal degeneration.
Furthermore, these individuals experience age-related changes
in the composition of their spinal cord, have reduced
physiological reserves, and may be less tolerant of certain
interventions.14,15 By summarizing current evidence, these
guidelines will help evaluate the safety and efficacy of various
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treatment modalities and provide guidance on the management
of elderly myelopathic patients.
Second, there is also an increased reported prevalence of
myelopathy in individuals aged 50 to 60 years, likely due to
improved diagnostic techniques. In the recent prospective
AOSpine studies, the mean age of patients (n ¼ 757) was
approximately 56 years,16,17 which is a decade younger than
the typical retirement age for many countries.17 Patients with
myelopathy experience greater functional impairment, a
decrease in social independence, and substantially reduced
quality of life. Long-term disability in patients aged 50 to 60
years also poses greater financial burden on society as individ-
uals in their mid-50s are at the peak of their working career.
These guidelines will therefore not only ensure appropriate
management in the elderly population but will also define treat-
ment strategies for patients whose professional duties and other
activities of daily living might be significantly impaired.
Finally, these guidelines aim to provide clinicians with gui-
dance that is evidence-based and representative of both the
state of existing literature and perspectives of various stake-
holders. The 3 main areas of focus are (1) the neurological
natural history of DCM; (2) the management of mild, moder-
ate, and severe myelopathic patients and the expected out-
comes of surgical and non-surgical treatment; and (3) the
management of nonmyelopathic patients with MRI evidence
of cord compression or canal stenosis.
These guidelines will provide the basis for more informed
and shared decision-making between clinicians and patients.
The ultimate goal of these guidelines is to improve outcomes
and reduce morbidity in patients with DCM by decreasing the
heterogeneity of management strategies and encouraging clin-
icians to make evidence-informed decisions.
Overall Objective
The main objective of this guideline is to outline how to best
manage patients with mild, moderate and severe myelopathy
and nonmyelopathic patients with evidence of cervical cord
compression.
Specific Scope and Aspects of Care
Specific conditions that are covered in this guideline include
 Degenerative cervical myelopathies:
 Spondylosis/osteophytosis
 Disc degeneration
 Disc herniation/bulging
 Hypertrophy of the ligamentum flavum
 Ossification of the posterior longitudinal ligament
 Calcification of the spinal ligaments
 Degenerative spondylolisthesis
 Facet hypertrophy
 Facet joint instability
 Subluxation
Specific conditions that are not covered in this guideline
include
 Other compressive myelopathies:
 Spinal epidural abscess
 Spinal epidural hematoma
 Syringomyelia
 Chiari malformation
 Spinal tumors
 Spinal cord tumors
 Noncompressive myelopathies:
 Traumatic spinal cord injury (including central cord
syndrome)
 Spinal cord infarction
 Inflammatory and immune myelopathies (eg, multi-
ple sclerosis, rheumatoid arthritis)
 Radiation myelopathy
 Infection
 Amyotrophic lateral sclerosis
 Radiculopathy
 Peripheral nerve entrapment
 Congenital hypermobility syndromes
The following aspects of care are addressed in this
guideline:
 Effectiveness and safety of nonsurgical treatment for
DCM.
 Effectiveness and safety of surgical treatment for DCM.
 The role of preoperative myelopathy severity and dura-
tion of symptoms on treatment outcomes. When is the
optimal time to operate? Should patients with mild mye-
lopathy be treated surgically?
 Monitoring and management strategies for nonmyelo-
pathic patients with evidence of cord compression. What
patients are at a high risk of myelopathy development?
Specific treatments or aspects of care that are not addressed
in this guideline include:
 The differential diagnosis of DCM.
 Relative efficacy, effectiveness, and safety of anterior
versus posterior surgery.
 Relative efficacy, effectiveness, and safety of lamino-
plasty versus laminectomy with fusion.
 Use of neuroprotective agents such as methylpredniso-
lone or riluzole.
 Novel imaging and diagnostic techniques.
 Diagnostic tools to quantify impairment.
Relevant Definitions
This guideline discusses management strategies for patients
with either symptomatic degenerative myelopathy or nonmye-
lopathic patients with evidence of cord compression.
The following definitions are important in order to under-
stand the scope of this guideline:
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 Cervical myelopathy is defined as a clinical disease
involving loss of fine motor control and coordination,
gait dysfunction with long tract signs and imaging evi-
dence of cervical cord compression.
 Degenerative cervical myelopathy is defined as sympto-
matic myelopathy caused by degenerative changes to the
spinal axis. These include osteoarthritic changes such as
spondylosis, disc herniation and facet arthropathy as
well as ligamentous aberrations, including calcification,
hypertrophy, or ossification of the ligamentum flavum
and posterior longitudinal ligament.4,18
 Cervical spondylotic myelopathy is defined as myelopa-
thy secondary to spondylotic changes or disc
degeneration.
 Ossification of the posterior longitudinal ligament is
defined as ectopic bone formation within the posterior
longitudinal ligament. Patients with OPLL may be
asymptomatic or present with signs and symptoms of
myelopathy.
 Nonmyelopathic patients have MRI evidence of spinal
cord compression and symptoms of neck pain but do not
present with signs of myelopathy.
 Radiculopathy is defined as compression or irritation of
a nerve as it exits the spinal canal. Radiculopathy may be
diagnosed through clinical, imaging and/or electrophy-
siological examination.
 The modified Japanese Orthopedic Association (mJOA)
scale is an investigator-administered DCM-specific
index that separately addresses motor function of the
upper and lower extremities, sensory function of the
upper extremities and sphincter function.19,20 A score
of 18 indicates normal function, whereas a lower score
reflects more severe neurological impairment. The
mJOA is composed of 2 dimensions, has moderate inter-
nal consistency, is responsive to change and demon-
strates both convergent and divergent validity.21 The
reliability of the mJOA has not been established.
 Based on the mJOA score,mildmyelopathy is defined as
15, moderate as 12 to 14, and severe as 11.
 The Nurick Score is a 6-grade clinician-administered
DCM-specific index that focuses on ambulation and
employment.20 Grade 0 ¼ root involvement without
spinal cord dysfunction, grade I ¼ signs of spinal cord
dysfunction without difficulty in walking, grade II ¼
difficulty in walking without effect on employment,
grade III ¼ difficulty in walking with effect on
full-time employment, grade IV ¼ can walk only with
someone else’s help or with the aid of a frame, and grade
V ¼ chair bound or bedridden.
 The Neck Disability Index is a patient-reported outcome
measure which incorporates several components of daily
living, including pain intensity, personal care, lifting,
reading, headaches, concentration, work, driving, sleep-
ing, and recreation.20 These 10 subscales are scored
from 0 ¼ no disability to 5 ¼ complete disability, sum-
mated and multiplied by 2. The higher the score, the
greater the disability, with 100 reflecting the maximum
score.
 The Visual Analog Scale (VAS) measures a patient’s
pain across a continuum from no pain to extreme pain
on an 11-point numerical rating scale.20
 Duration of symptoms is the patient-reported time from
symptom onset to treatment.
 The minimum clinically important difference (MCID) is
the smallest change in a treatment outcome that a patient
or clinician would define as meaningful.22-24
 Disease natural history refers to the progress of a dis-
ease over time in the absence of intervention.
 A successful outcome has been defined differently across
studies. The primary objective of treatment is to halt
disease progression. Other objectives include to improve
function, disability, pain, and quality of life. Success has
been defined based on final postoperative score (eg,
mJOA  16), recovery rate or achieving a MCID.
 A complication is a treatment-related adverse event.
Summary of Contents
Five systematic reviews were conducted to summarize the cur-
rent body of evidence. Table 1 summarizes the key clinical
questions and main results from these reviews. A summary
of our recommendations is provided below.
Patients with severe DCM: We recommend surgical
intervention for patients with severe DCM. (Grade:
Strong Recommendation; Moderate Evidence)
Patients with moderate DCM: We recommend surgical
intervention for patients with moderate DCM. (Grade:
Strong Recommendation; Moderate Evidence)
Patients with mild DCM: We suggest offering surgical
intervention or a supervised trial of structured rehabi-
litation for patients with mild DCM. If initial nono-
perative management is pursued, we recommend
operative intervention if there is neurological dete-
rioration and suggest operative intervention if the
patient fails to improve. (Grade: Weak Recommenda-
tion; Very Low to Low Evidence)
Nonmyelopathic patients with evidence of cord compres-
sion without signs and symptoms of radiculopathy:We
suggest not offering prophylactic surgery for non-
myelopathic patients with evidence of cervical cord
compression without signs or symptoms of radiculo-
pathy. We suggest that these patients be counseled as
to potential risks of progression, educated about rele-
vant signs and symptoms of myelopathy, and be fol-
lowed clinically. (Grade: Weak Recommendation; No
Evidence Identified, based on expert opinion)
Nonmyelopathic patients with image evidence of cord
compression and clinical and/or electrophysiological
evidence of radiculopathy: Nonmyelopathic patients
with cord compression and clinical evidence of radi-
culopathy with or without electrophysiological
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Table 1. Evidence Summary from the Systematic Reviews used to Develop our Recommendations.
Title Key Clinical Questions Main Results
Pathophysiology and natural history of
cervical spondylotic myelopathy6
 What is the natural history of DCM?
 What are the risk factors for
progression of DCM?
Moderate Evidence: 20%-62% of patients with
symptomatic DCM deteriorate by 1 point on
the JOA 3-6 years after initial assessment.
Moderate Evidence: Patients with DCM worsen in
performing activities of daily living with
nonoperative treatment at 1- (6%), 2- (21%),
3- (28%), and 10-year (56%) follow-up.
Low Evidence: Circumferential spinal cord
compression is associated with neurological
deterioration.
The natural history of degenerative cervical
myelopathy and the rate of hospitalization
following spinal cord injury: an updated
systematic review
Same as above Low Evidence: The rate of hospitalization due to
spinal cord injury in patients with myelopathy
secondary to OPLL is 4.8 per 1,000 person
years. The rate in a healthy population is 0.18
per 1,000 person years (HR: 32.2, 95% CI: 10.4
to 99.0). The rate in individuals with a diagnosis
of DCM not caused by OPLL is 13.9 per 1,000
person years.
Low Evidence: The rate of severe disability in
patients with a diagnosis of myelopathy
secondary to OPLL is 3.4 per 1,000 person
years.
Nonoperative management of cervical
myelopathy: a systematic review25
 What is the evidence of the efficacy,
effectiveness and safety of nonoperative
treatment in patients with DCM
compared with surgical intervention?
 Do the outcomes of nonoperative
treatment vary according to myelopathy
severity?
 Are minor injuries associated with
neurological deterioration among
patients with cervical myelopathy or
asymptomatic cervical cord compression
treated nonoperatively?
Low Evidence: There is no difference in (m)JOA
scores between “milder” (mJOA 12) patients
treated operatively versus nonoperatively: (1)
scores were similar at 1-, 2-, 3-, and 10-year
follow-up (RCT); and (2) there were no
differences in scores after 2-3 years.
Low Evidence: In patients with “milder” CSM
(mJOA  12), surgery results in a slower
10-meter walk test time compared to
nonoperative treatment at 3-year follow-up.
Low Evidence: There is no difference between
operative and nonoperative care in the
proportion of patients who had worse or
improved clinician-based or patient-reported
daily activity scores at 1-, 2-, 3-, and 10-year
follow-up.
Nonoperative versus operative management
for the treatment degenerative cervical
myelopathy: an updated systematic review
Same as above Low Evidence: The incidence of hospitalization for
spinal cord injury is greater in DCM patients
treated conservatively than those undergoing
surgery.
Change in function, pain and quality of life
following structured nonoperative
treatment in patients with degenerative
cervical myelopathy: a systematic review
 What is the change in function, pain and
quality of life following nonoperative
treatment?
 Is there variability in the change in
function, pain and quality of life following
different types of nonoperative
treatment?
 Are there differences in outcomes
following nonoperative treatment
between certain subgroups (eg, baseline
severity score, duration of symptoms).
 What are the negative outcomes and
harms associated with structured
nonoperative treatment?
All findings were based on very low evidence and
should be interpreted cautiously. Important
findings included:
There were no clinically or statistically significant
differences between mJOA/JOA scores at
baseline and follow-up following structured
nonoperative treatment. Follow-up durations
ranged from 30 to 74.0 months.
23%-54% of patients received surgery following
structured nonoperative treatment. Follow-up
durations ranged from 30 to 74.0 months.
(continued)
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confirmation are at a higher risk of developing myelo-
pathy and should be counseled about this risk. We
suggest offering either surgical intervention or nono-
perative treatment consisting of close serial follow-up
or a supervised trial of structured rehabilitation. In the
event of myelopathic development, the patient should
be managed according to the recommendations above.
(Grade: Weak Recommendation; Low Evidence).
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